Drugs / SV-102
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05544227 | Feb 2023 → Dec 2024 | castration-resistant prostate carcinoma | Williams Cancer Foundation | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06533644 | May 2025 → Apr 2028 expected | castration-resistant prostate carcinoma | Syncromune, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 7
| Date | Issuer | Release |
|---|---|---|
| 2025-12-04 | Syncromune, Inc. | Results Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting syncromune.com ↗
Among the 15 patients enrolled in the single-arm Phase 1 trial, 13 (87%) had skeletal metastases at baseline, and following SYNC-T therapy, all bone metastases resolved in seven (54%) of these patients. |
| 2025-11-20 | Syncromune, Inc. | Results Syncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting syncromune.com ↗
The data will be presented digitally as an electronic poster and highlights findings from the now-concluded Phase 1 study of SYNC-T Therapy SV-102 in metastatic prostate cancer, with a focus on radiographic resolution of bone metastases observed in patients who achieved complete responses. |
| 2025-06-02 | Syncromune, Inc. | Results Syncromune® Inc. Presents Positive Results from SYNC-T™ Therapy SV-102 Phase 1 Metastatic Prostate Cancer Trial at ASCO 2025 syncromune.com ↗
Final clinical data demonstrate an 87% overall response rate in patients with metastatic prostate cancer |
| 2025-05-23 | Syncromune, Inc. | Results Syncromune® Inc. Announces Publication of Abstract on SYNC-T™ Therapy SV-102 Phase 1 Data for Metastatic Prostate Cancer at ASCO 2025 Annual Meeting syncromune.com ↗
The data demonstrate that SYNC-T Therapy achieved an overall response rate (ORR) of 87%, including a complete response (CR) rate of 53%, in patients with metastatic castration-resistant prostate cancer or who had refused hormonal therapy. |
| 2024-07-01 | Syncromune, Inc. | Regulatory Syncromune Granted FDA Fast-Track Designation for SYNC-T™ SV-102 for the Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) syncromune.com ↗
Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for solid tumor cancers, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for SYNC-T SV-102 therapy, its lead candidate for the treatment of patients with metastatic castrate-resistant prostate cancer (mCRPC). |
| 2024-05-30 | Syncromune, Inc. | Regulatory Syncromune® Inc. Announces FDA Clearance of IND Application for SYNC-T™ SV-102, a First-In-Class Combination Multi-Target Immunotherapy for Metastatic Castrate-Resistant Prostate Cancer syncromune.com ↗ |
| 2024-04-08 | Syncromune, Inc. | Results Syncromune® Inc. Presents Positive Results from SYNC-T™ SV-102 Phase 1 Trial at AACR Annual Meeting 2024 syncromune.com ↗
The trial, involving patients with metastatic castrate-resistant prostate cancer (mCRPC), showed an overall response rate (ORR) of 85%. |
All press releases naming this drug 10 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SV-102 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06533644 ↗ |
| Route | Other | “the intratumoral infusion of a low-dose multi-component drug product” NCT05544227 ↗ |